Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 48 of 216 for:    Lamotrigine

Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04156035
Recruitment Status : Not yet recruiting
First Posted : November 7, 2019
Last Update Posted : November 7, 2019
Sponsor:
Collaborator:
Boehringer Ingelheim
Information provided by (Responsible Party):
Simone Grimm, Medical School Berlin

Brief Summary:
This study is firstly designed to investigate acute and delayed effects of a single dose of ketamine on functional brain changes during emotional and cognitive challenges and at rest. Secondly, it aims to investigate whether functional brain changes after ketamine require increased glutamatergic signaling and will accordingly be modulated after pretreatment with lamotrigine.

Condition or disease Intervention/treatment Phase
Emotions Drug: Lamotrigine Drug: Ketamine Drug: Placebo Pretreatment Drug: Placebo Infusion Not Applicable

Detailed Description:

Despite the rapid antidepressant effects of ketamine, its increasing use as an AD and the recent (2019) FDA approval of ketamine nasal spray as medication for treatment-resistant depression, the exact neurobiological mechanisms underlying its effects remain unclear.

There are numerous reasons, why so far there has been no coherent explanatory framework. Most previous studies focused on investigating a single domain such as functional connectivity (e.g. Deakin et al., 2008; Scheidegger et al., 2012), functional brain changes to either cognitive (e.g. Honey et al., 2005; Driessen et al., 2013) or emotional challenge (e.g. Scheidegger & Grimm et al., 2016; Reed et al., 2019), perfusion (e.g. Pollack et al., 2015), magnetic fields (Salvadore et al., 2010) or neurotransmitter concentrations (e.g. Abdallah et al., 2018). Small sample sizes of as little as 8 subjects, the lack of a control group, the limited number of timepoints for measurement of the above-mentioned parameters, and the failure to modulate glutamatergic signalling after ketamine further limit the informative value of previous findings. What is therefore urgently needed in order to better understand the mechanisms of ketamine, is a study that combines neuroimaging in several modalities, investigates acute as well as delayed effects of ketamine and applies an approach to modulate glutamatergic signaling after ketamine.

Accordingly, this study is designed to investigate acute and delayed effects of a single dose of ketamine on functional brain changes during emotional and cognitive challenge and at rest as well as to investigate the functional significance of increased glutamatergic signalling after ketamine. Measurement of functional brain changes will occur during (acute) and 24 hrs. after a single dose of ketamine, as differential effects are hypothesized. To modulate glutamatergic signaling after ketamine, a lamotrigine pretreatment protocol will be used. It is hypothesized that functional brain changes previously linked to ketamine require increased glutamatergic signaling and will be attenuated by pretreatment with lamotrigine. To test these hypotheses, we will implement a randomized, placebo-controlled, parallel-group design with 3 treatment conditions (lamotrigine + ketamine, placebo + ketamine, placebo + placebo). All subjects will undergo two scanning sessions (acute + post 24 hrs.). In order to include baseline values as covariates in the analyses, imaging will begin 10 minutes before infusion of ketamine/placebo. Pretreatment with lamotrigine or matching placebo will occur 2 hours before the ketamine/placebo infusion. Blood samples will be taken at 0:30, 1:00, 1:30, 2:55 and 4 hours following oral drug administration to determine the plasma pharmacokinetics of lamotrigine, and at 40 minutes after commencing ketamine infusion to confirm target ketamine plasma levels.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Trial to Study Acute and Delayed Effects of a Single Dose of Ketamine on Functional Brain Changes During Emotional/ Cognitive Challenges and at Rest and Their Modulation by Lamotrigine in Healthy Subjects
Estimated Study Start Date : January 2020
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Lamotrigine + Ketamine
Pretreatment with lamotrigine will occur 2 hours before the ketamine infusion
Drug: Lamotrigine
Orally; 300 mg

Drug: Ketamine
Intravenously; 0.12 mg/kg during the first minute followed by a continuous infusion of approximately 0.31 mg/kg/h over approx. 40 min

Experimental: Placebo + Ketamine
Pretreatment with placebo will occur 2 hours before the ketamine infusion
Drug: Ketamine
Intravenously; 0.12 mg/kg during the first minute followed by a continuous infusion of approximately 0.31 mg/kg/h over approx. 40 min

Drug: Placebo Pretreatment
Lamotrigine Placebo

Placebo Comparator: Placebo + Placebo
Pretreatment with placebo will occur 2 hours before the placebo infusion
Drug: Placebo Pretreatment
Lamotrigine Placebo

Drug: Placebo Infusion
Ketamine Placebo




Primary Outcome Measures :
  1. Functional brain changes induced by emotional and cognitive challenge [ Time Frame: Measurements will occur during (acute) and 24h after (delayed) a single dose of ketamine ]

    The primary endpoints of efficacy are the functional brain changes induced by emotional and cognitive challenge during ketamine infusion as compared to placebo and to the responses during ketamine infusion after Lamotrigine pretreatment during and after (post 24 hrs.) in following brain regions (bilateral):

    • Amygdala
    • Hippocampus
    • Dorsolateral Prefrontal Cortex
    • Anterior cingulate Cortex
    • Insula


Secondary Outcome Measures :
  1. Changes in resting- state functional connectivity in default- mode network (DMN) and affective network (AN) [ Time Frame: Measurements will occur at baseline, during and 24h after a single dose of ketamine ]
    Changes in resting- state functional connectivity in default- mode network (DMN) and affective network (AN) in the following brain regions (bilateral): Amygdala, Hippocampus, Dorsolateral Prefrontal Cortex, Anterior cingulate Cortex and Insula. During the resting state scan, During this scan, subjects are asked to relax and to keep their eyes open.

  2. Changes in cerebral blood flow in predefined brain regions [ Time Frame: Measurements will occur during and 24h after a single dose of ketamine ]
    Changes in cerebral blood flow (ASL) in in the following brain regions (bilateral): Amygdala, Hippocampus, Dorsolateral Prefrontal Cortex, Anterior cingulate Cortex and Insula. During ASL, subjects engage in no special task, but are asked to close their eyes and relax. ASL provides quantitative parametric images of tissue perfusion.

  3. Association between functional brain changes during emotional and cognitive challenge and ketamine- induced dissociative state [ Time Frame: Measurements will occur during and 24h after a single dose of ketamine ]
    Dissociate state will be investiagted using the Dissoziations-Spannungs-Skala akut (DSS-akut, Stiglmayr et al. 2003).

  4. Association between changes in resting- state functional connectivity and ketamine- induced dissociative state [ Time Frame: Measurements will occur during and 24h after a single dose of ketamine ]
    Dissociate state will be investiagted using the Dissoziations-Spannungs-Skala akut (DSS-akut, Stiglmayr et al. 2003).

  5. Blood concentration of lamotrigine [ Time Frame: Measurements will occur at baseline as well as 0.30, 1:00, 1:30, 2:55 and 4h following drug administration ]
    Blood samples are taken to determine citrate plasma concentration of Lamotrigine to assess plasma levels during fMRI assessments.

  6. Blood concentration of ketamine [ Time Frame: Measurements will occur approx. 40 minutes after commencing ketamine infusion ]
    Blood samples are taken to determine citrate plasma concentration of Ketamine to confirm target exposures (plasma levels) during assessments.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Main Inclusion Criteria:

  • From 18 to 45 years of age, inclusive
  • Body Mass Index (BMI) between 18.0 and 28.5 kg/m2, inclusive
  • Healthy on the basis of physical examination, medical history, vital signs, clinical laboratory tests, and 12-lead ECG

Main Exclusion Criteria:

  • Clinically relevant allergy or drug hypersensitivity
  • A history of psychiatric or neurologic disorders
  • Alcohol or substance dependence within the last 12 months from screening
  • A positive urine drug screen at any visit
  • MR exclusion criteria, elevated intracranial pressure or glaucoma
  • Hypertonia, cardiac insufficiency, myocardial infarct within last 6 months
  • Liver or renal function disorder
  • Prescription of psychotropic medication within 28 days prior to screening
  • Non-prescription medication, including analgesics and supplements such as vitamins and herbal supplements within 48 hours prior to the baseline visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04156035


Contacts
Layout table for location contacts
Contact: Simone Grimm, PhD 0049450 ext 517778 simone.grimm@medicalschool-berlin.de

Locations
Layout table for location information
Germany
Medical School Berlin
Berlin, Germany, 12247
Sponsors and Collaborators
Charite University, Berlin, Germany
Boehringer Ingelheim
Investigators
Layout table for investigator information
Principal Investigator: Simone Grimm, PhD Medical School Berlin

Layout table for additonal information
Responsible Party: Simone Grimm, Prof., Medical School Berlin
ClinicalTrials.gov Identifier: NCT04156035     History of Changes
Other Study ID Numbers: MSB-C001
First Posted: November 7, 2019    Key Record Dates
Last Update Posted: November 7, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lamotrigine
Ketamine
Anticonvulsants
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Calcium Channel Blockers
Membrane Transport Modulators
Calcium-Regulating Hormones and Agents
Antipsychotic Agents
Tranquilizing Agents
Psychotropic Drugs
Sodium Channel Blockers